Intervacc comments on the trading halt of the company's share on Nasdaq First North
Stockholm, December 15, 2021 - Nasdaq Stockholm has decided to temporarily stop trading in Intervacc after a volatile trading session and a decline in the share price. The reason for the price decline is speculation in social media about the company's vaccine Strangvac, following the Medical Products Agency having published a so-called monograph on the vaccine.
The Medical Products Agency states in the monograph: “Experience has shown that it is difficult to produce a vaccine against strangles that can effectively prevent horses from becoming infected, spreading infection and developing